Clinical Trials Logo

Cystic Fibrosis (CF) clinical trials

View clinical trials related to Cystic Fibrosis (CF).

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05818319 Recruiting - Clinical trials for Cystic Fibrosis (CF)

Cystic Fibrosis in the Kidney: Monitoring the Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in Urine After a Short Pause of Therapy

Start date: June 1, 2023
Phase: N/A
Study type: Interventional

In cystic fibrosis (CF) renal base excretion is impaired, due to mutations in the Cystic Fibrosis Transmembrane Regulator (CFTR) gene, since CFTR function is crucial in regulation of the kidney's HCO3- excretion. The investigators suggest that challenged urine HCO3- excretion is a biomarker of CFTR function, which can be used to evaluate the extent of CFTR dysfunction and the possible correcting effects of CFTR modulating therapy. This study aims to evaluate changes in challenged urine HCO3- excretion in CF patients, who are currently in treatment with the triple CFTR modulator combination therapy, Elexacaftor/tezacaftor/ivacaftor (ETI), before, during, and after a short treatment pause.

NCT ID: NCT01851642 Recruiting - Clinical trials for Alpha-1 Antitrypsin Deficiency

Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs

Start date: August 9, 2007
Phase:
Study type: Observational

The purpose of this study is to look at how Alpha-1-antitrypsin (AAT) deficiency and Cystic Fibrosis (CF) affect white blood cells in the lungs, called macrophages, and their ability to work.